Takeda Stresses Orexin Commitment Despite Setback
Big Share Buyback As Q2 Reported
Executive Summary
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.
You may also be interested in...
Takeda’s Maribavir Post-Transplant CMV Indication Should Not Be Limited By Resistance, US Panel Says
Advisory committee unanimously endorses novel antiviral for treatment of post-transplant patients with refractory/resistant cytomegalovirus infection, and in the process rejects US FDA’s proposal to distinguish target population based upon genetic resistance.
Keeping Track: Takeda’s Exkivity Clears US FDA; BeiGene’s Busy Summer
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Takeda Looks To Ride 'Wave 1' To JPY5tn Target
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.